大家好欢迎参加本次信达医药九州通2023年年报2024年QE报解读电话会议目前所有参会者均处于静音状态现在开始播报免责声明声明播报完毕后主持人可直接开始发言谢谢 本次电话会议仅面向信达证券签署服务协议的签约客户或收邀客户在任何情况下本电话会议的信息或所表述的意见不构成对任何人的投资建议也没有考虑到客户特殊的投资目标财务状况或需求会议中如设计第三方专家发言其内容仅代表专家个人观点根据监管规定未经信达证券说明授权严禁任何机构或个人转发转载 录音制作并传播禁药或引用会议的任何部分内容等对于违反上述情形的信达证券对此等行为不承担任何责任且信达证券将保留一切法律权利感谢您的理解和支持好的各位同学大家上午好我是信达证券医药首席分析师唐艾军跟我一起在线的话还有我们几个同事张忠涛 那上周五的时候呢九月初发布了这个2023年年报和2024年年报那么二三年的话公司营收是创了历史新高来超过了一千五百亿那么规模低润的话达到了19.61亿也是同比增长了13.06%非常稳健那么尤其是这个经营性的先进流的话呢是达到了47.48亿啊同比有19%的一个增长非常亮丽那么公司的这个医药分销业务的话呢呃市占第一市值面提高的一个基础上那么总代理的品牌 ...

证券研究报告·公司点评报告·医药商业 九州通（600998） 2023年报&2024一季报点评：业务转型升级， 2024 年 04月 29日 新三年战略实施成效显著 证券分析师 朱国广 买入（维持） 执业证书：S0600520070004 zhugg@dwzq.com.cn [Table_EPS] 盈利预测与估值 2022A 2023A 2024E 2025E 2026E 股价走势 营业总收入（百万元） 140,424 150,140 166,851 185,171 204,891 同比（%） 14.72 6.92 11.13 10.98 10.65 九州通 沪深300 12% 归母净利润（百万元） 2,085 2,174 4,778 3,415 3,777 9% 6% 同比（%） (14.84) 4.27 119.77 (28.53) 10.61 03 %% -3% EPS-最新摊薄（元/股） 0.53 0.56 1.22 0.87 0.97 -- 96 %% -12% P/E（现价&最新摊薄） 15.39 14.76 6.72 9.40 8.50 --- 211 185 %%% [ [TT aab bl ...

证券研究报告：医药生物 | 公司点评报告 2024年4月28日 股票投资评级 九州通(600998) 经营质量持续提升，创新战略推动“千亿航母”行 买入|维持 稳致远 个股表现  经营质量持续提升，全力推进高质量发展 公司发布 2023 年年报：2023 年公司实现营收 1501.40 亿元 九州通 医药生物 11% （+6.92%），归母净利润21.74亿元（+4.27%），扣非净利润19.60亿 7% 元（+13.06%）。2023年公司扣非净利润实现快速增长。 3% -1% 同时公司发布2024年一季报：2024Q1公司实现营业收入404.72 -5% -9% 亿元（-3.85%），归母净利润 5.38 亿元（-4.19%），扣非归母净利润 -13% -17% 5.22亿元（-9.01%）。公司营业收入、归母净利润、扣非归母净利润 -21% 小幅下降，主要原因是 2023Q1 受流感等季节性疾病因素影响，相关 -25% -29% 品种销量大增，营业收入、净利润等基数较高；而 2024Q1 受季节性 2023-04 2023-07 2023-09 2023-11 2024-02 2024-04 疾病因素 ...

Financial Performance - Company's operating revenue reached a historical high of 150.14 billion yuan, a year-on-year increase of 6.92%[2] - Non-GAAP net profit attributable to the parent company was 1.96 billion yuan, a year-on-year increase of 13.06%[2] - Operating cash flow reached a record high of 4.748 billion yuan, a year-on-year increase of 19.10%[2] - Revenue for 2023 reached 150.14 billion RMB, a 6.92% increase compared to 2022[27] - Net profit attributable to shareholders in 2023 was 2.17 billion RMB, up 4.27% year-over-year[27] - Operating cash flow increased by 19.10% to 4.75 billion RMB in 2023[27] - Total assets grew by 0.52% to 92.79 billion RMB at the end of 2023[27] - Basic earnings per share rose 7.84% to 0.55 RMB in 2023[28] - Weighted average return on equity (ROE) increased by 0.06 percentage points to 9.04% in 2023[28] - The company achieved operating revenue of 150.14 billion yuan, a year-on-year increase of 6.92%, and net profit attributable to the parent company of 2.174 billion yuan, a year-on-year increase of 4.27%[172] - The company's main business revenue reached 149.981 billion yuan, a year-on-year increase of 6.91%, with a gross profit of 12.049 billion yuan, a year-on-year increase of 10.48%[173] Business Segments and Revenue Growth - The company's pharmaceutical industry self-produced and OEM business sales revenue reached 2.476 billion yuan[4] - The company's total agency brand promotion business (CSO) sales revenue reached 19.584 billion yuan, a year-on-year increase of 52.45%[5] - The company's pharmaceutical total agency brand promotion business sales revenue reached 10.696 billion yuan, a year-on-year increase of 60.82%[5] - The company's medical device total agency brand promotion business sales revenue reached 8.888 billion yuan, a year-on-year increase of 31.44%[5] - Total agency brand promotion business revenue grew 46.01% in 2023, with a 52.45% increase in gross profit[30] - Pharmaceutical new retail business revenue increased by 10.95% in 2023[30] - Digital logistics technology and supply chain solutions revenue grew 28.45% in 2023, with a 49.44% increase in gross profit[30] - Total agency brand promotion business revenue reached 19.584 billion yuan, a year-on-year increase of 46.01%[40] - Pharmaceutical new retail business revenue increased by 10.95% year-on-year[40] - Digital logistics technology and supply chain solutions revenue increased by 28.45% year-on-year[40] - Total agency brand promotion business (CSO) achieved sales revenue of 19.584 billion yuan, a year-on-year increase of 46.01%, with a gross profit of 2.789 billion yuan, up 52.45% year-on-year[43] - Pharmaceutical total agency brand promotion business achieved sales revenue of 10.696 billion yuan, a year-on-year increase of 60.82%, with a gross profit of 2.267 billion yuan, up 54.83% year-on-year[43] - Medical device total agency brand promotion business achieved sales revenue of 8.888 billion yuan, a year-on-year increase of 31.44%, with a gross profit of 522 million yuan, up 42.91% year-on-year[44] - Pharmaceutical industry self-production and OEM business achieved sales revenue of 2.476 billion yuan, with a gross profit margin of 23.84% and a gross profit of 590 million yuan[45] - JiuXin Traditional Chinese Medicine Group achieved self-production sales revenue of 1.2 billion yuan, with a gross profit margin of 25.6% and a gross profit of 307 million yuan[46] - Beijing Jingfeng Pharmaceutical Group achieved revenue of 466 million yuan, with 150+ products in production and 8 drugs passing consistency evaluation[46] - The company introduced 98 new high-quality products, including 2 with sales exceeding 100 million yuan and 10 with sales exceeding 10 million yuan[43] - The company completed the upgrade of the "Quanqing Health" brand and implemented the full-case brand upgrade for Kefei[43] - The company focused on developing large surgical, cardiovascular intervention, and IVD national platform distribution businesses, optimizing logistics systems and digital platforms[44] - The company produced 36,234 batches of traceable herbal pieces, with a total annual output of 8,991.44 tons, achieving full traceability in the herbal medicine supply chain[46] - Product sales revenue reached 1.882 billion yuan, with Jiuxin Traditional Chinese Medicine focusing on high-quality and safe products, offering a wide range of categories including precious herbs, fine drinks, and formula drinks[47] - The company has obtained 10 MAH Class II product registration certificates and 25 Class I product filing certificates, with 173 OEM medical device specifications and 424 drug OEM specifications, enhancing product competitiveness through self-developed and OEM products[47] - The "Wan Dian Jia Meng" (10,000 Store Franchise) plan has achieved significant progress, with 21,192 direct and franchise pharmacies by the end of Q1 2024, covering 31 provinces and 293 cities, and a target of over 30,000 stores by 2025[49] - Franchise pharmacy sales revenue reached 3.48 billion yuan, an 83.25% year-on-year increase, with 3,900 professional pharmacies, dual-channel pharmacies, and hospital-side stores, including 3.3 billion yuan in prescription outflow revenue[49] - B2C e-commerce total agency and sales business achieved 1.215 billion yuan in revenue, a 26.8% year-on-year growth, with rapid expansion on new e-commerce platforms like Douyin and Kuaishou[50] - The company's B2B e-commerce terminal sales channel generated 17.326 billion yuan in revenue, with the Yaojiujiu B2B platform achieving 11.241 billion yuan in self-operated transactions and covering 99% of administrative regions[51] - Retail e-commerce platform business revenue reached 6.085 billion yuan, an 11.47% year-on-year increase, with sales to JD.com and Alibaba's self-operated platforms exceeding 4.24 billion yuan, a 16.69% increase[52] - The company's logistics Bb/BC integrated warehousing and distribution system supports efficient supply chain logistics, enabling "zero inventory" for online and offline customers and sharing 100,000 product specifications[52] - The company has completed the "Bb/BC integrated warehousing and distribution" logistics service system, covering 6 "BC integrated warehouses" in Hubei, Shanghai, Guangdong, Beijing, Tianjin, and Zhejiang, and has upgraded 24 logistics centers to "Bb integrated" operations across 24 provinces[53] - The "Bb integrated project" was recognized as a leading case in digital transformation by the China Listed Companies Association and the "2023 Digital Economy Development Typical Case" by the Securities Daily[53] - The company launched the "New Medical" strategy, targeting the 321,000 clinics/outpatient departments in China, aiming to provide integrated supply chain and operational services to enhance terminal control[56] - The internet medical business achieved revenue of 156 million yuan in the reporting period, with 31 target hospitals connected to the prescription transfer platform[57] - The company is advancing the REITs project, planning to use 3.3 million square meters of pharmaceutical logistics assets as underlying assets, with the first batch of assets being the Wuhan logistics center, covering 172,000 square meters[59] - The company's digital transformation strategy has established a comprehensive digital platform, including ERP, logistics, and financial systems, supporting multiple business scenarios such as retail, new medical, and pharmaceutical distribution[61] - The company's financial shared cloud platform and "Bb integrated project" were selected as digital transformation典型案例 by the China Listed Companies Association in 2022 and 2023, respectively[61] - The company's "Bb/BC integrated warehousing and distribution project" was recognized as a "2023 Digital Economy Development Typical Case" by the Securities Daily[61] - The company's digital transformation projects, including the orthopedic smart service platform and retail digital operation platform, have been optimized and implemented[61] - The company aims to transition from a traditional pharmaceutical commercial enterprise to a technology-driven platform service provider through digital transformation[61] - The company's revenue from hospital markets reached 54.139 billion yuan, a year-on-year increase of 11.32%, with 268,600 medical institutions covered[62] - Revenue from tiered hospitals was 38.751 billion yuan, up 9.41% year-on-year, covering over 80% of tiered hospitals nationwide[62] - Revenue from primary medical institutions was 7.425 billion yuan, a year-on-year increase of 21.33%, covering over 60% of community health centers and township hospitals[63] - Revenue from private medical institutions was 7.963 billion yuan, up 12.19% year-on-year, serving major private medical groups[63] - The medical device segment achieved sales revenue of 32.815 billion yuan, a year-on-year increase of 11.66%, with 247,500 product specifications[63] - The company's orthopedic Chang'e intelligent service platform was completed, enhancing data service capabilities in the medical device field[64] - The traditional Chinese medicine (TCM) segment achieved sales revenue of 4.2 billion yuan, a year-on-year increase of 14.02%, with a gross profit of 776 million yuan[65] - The TCM segment covers 31 provinces and has established over 30 TCM production bases, with 40 varieties on the quality traceability platform[65] - The company partnered with leading domestic and foreign pharmaceutical companies, including Huarun Sanjiu, Yangtze River Pharmaceutical, and Novo Nordisk, to provide full-chain digital services[66] - Collaborations with medical device companies such as Mindray, MicroPort, and Philips enabled rapid supply to terminal markets through B2B/B2C/O2O platforms[66] - The company signed a strategic cooperation agreement with Johnson & Johnson, covering surgical, orthopedic, and interventional solutions, with a total value of nearly $500 million[67] - The company's logistics system for the "i Maotai" digital marketing platform achieved a peak daily order volume of 216,000 and a peak monthly order volume of 1.91 million[68] - The company's logistics subsidiary, Jiuzhou Logistics, was recognized as one of Maotai Group's 23 strategic suppliers, standing out from over 2,000 suppliers[68] - The company's BC integrated warehouse in Hangzhou achieved a peak daily order volume of 216,000 and a peak monthly order volume of 1.91 million, while the Tianjin warehouse achieved a peak daily order volume of 20,000 and a peak monthly order volume of 350,000[68] - The company's logistics subsidiary, Jiuzhou Cloud Intelligence, completed a large-scale modern high-end intelligent pharmaceutical warehousing and logistics center project for Shandong Yiyang Health Group[69] - The company signed a memorandum of cooperation with Vietnam Airlines Logistics and Vietnam International Service and Trade Investment to collaborate on logistics information technology and supply chain solutions[70] - The company held the "2023 Jiuzhoutong Financial Institutions Seminar," inviting 32 major financial institutions to discuss future cooperation directions, including expanding credit lines and innovating credit products[71] - The company formed a joint venture, Hubei Jiuzhou Pharmaceutical Supply Chain Co., Ltd., to promote the development of the pharmaceutical supply chain industry in Hubei Province[73] - The company signed a strategic cooperation agreement with Tencent Health to upgrade digital management services, financial payment services, and business intelligence services[74] - The company established a joint artificial intelligence laboratory with Peking University Wuhan Artificial Intelligence Research Institute to enhance digital management and intelligent supply chain systems[74] - The company donated a total of over 3.4 million yuan to support education in 2023, including the construction of the Egret Kindergarten in Ulanhot, Inner Mongolia[75] - The company's 2022 ESG report was rated "A" by Wind ESG and ranked 2nd in the pharmaceutical business category in the 2023 Huazheng ESG rating[75] - The company donated automatic external defibrillators worth over 180,000 yuan to the Red Cross Society of Yingcheng City, Hubei Province, installed in 12 public places with high foot traffic[75] - The company actively participated in disaster relief efforts, organizing donations for the July 2023 floods in Beijing-Tianjin-Hebei and the December 2023 earthquake in Gansu[75] - The company was awarded the "Charitable Donation Enterprise" honor at the first Hubei Charity Awards in September 2023[75] - The "Opinions of the CPC Central Committee and the State Council on Promoting the Development and Growth of the Private Economy" (31 measures) was issued in July 2023, providing strong policy support for private enterprises like the company[76] - In November 2023, eight government departments jointly issued the "Notice on Strengthening Financial Support Measures to Promote the Development and Growth of the Private Economy", proposing 25 specific measures to support private enterprises[79] - The company, as a leading private enterprise in the pharmaceutical distribution industry, will benefit from the financial support policies, which will reduce financing costs and expand financing channels[80] - By 2025, the national and provincial centralized drug procurement is expected to cover more than 500 varieties[81] - The company's sales revenue in public hospitals has achieved a compound annual growth rate of 10.58% over the past three years, with the number of effective customers rapidly increasing to 13,800[85] - Over 70% of the company's existing business is in pharmacies and third-tier markets, benefiting from the outflow of hospital prescriptions and the flow of chronic disease medications to third-tier markets[85] - The company has actively promoted real-world data research on innovative drugs in private hospitals, fostering collaboration opportunities with innovative drug companies[85] - The "dual-channel" policy has been implemented nationwide, covering 2,612 drugs, with reimbursement ratios mostly ranging from 70% to 80%[88] - The company has expanded its business coverage in public hospitals, significantly benefiting from the centralized procurement policy[85] - The company has leveraged its supply chain advantages to secure distribution rights for centralized procurement products and opportunities for total agency promotion in the out-of-hospital market[86] - The company has been actively promoting the development of innovative drugs in private hospitals, enhancing collaboration with innovative drug companies[85] - The company has seen steady growth in sales scale in private hospitals through improved logistics management and supply chain services[85] - The company has capitalized on the expansion of the retail market due to the "dual-channel" and "outpatient coordination" policies[87] - The company has benefited from the dynamic adjustment of the number of drugs included in the "dual-channel" management, with the minimum number being 169 and the maximum being 529[88] - The number of "dual-channel" pharmacies in Shandong Province is expected to exceed 700 by the end of September 2023, with a fund payment ratio of around 70% and no less than 85% for primary medical institutions[89] - By the end of Q1 2024, the company has expanded its directly operated and franchised pharmacies to 21,192, with 3,900 specialty pharmacies, dual-channel pharmacies, and hospital-adjacent stores (including franchised stores)[91] - The company's Good Pharmacist pharmacies in Wuhan have been included in outpatient统筹 management, benefiting from policies such as "outpatient统筹," "dual-channel," and "seven unifications"[91] - The "clinic filing system" was implemented nationwide in 2023, leading to a potential rapid increase in the number of clinics in China[92] - The number of clinics in China reached 321,000 by the end of 2022, with 59,848 new clinics registered in the past year, a 75% increase year-on-year[93] - The clinic medication market in China is growing at a double-digit rate annually, with a market size approaching 200 billion yuan[93] - Jiuzhou Tong's "New Medical" strategy focuses on building a "Digital Medical + Supply Chain" industrial service platform targeting clinic customers, leveraging its strong supply chain capabilities and advanced information management systems[94] - The strategy includes a smart clinic solution combining auxiliary diagnosis systems, ERP systems, patient management systems, and doctor management systems to improve clinic operational efficiency[94] - Jiuzhou Tong aims to provide a turnkey solution for new clinics and drive business growth by integrating upstream supplier resources in specialized fields such as dentistry, medical aesthetics, and traditional Chinese medicine[94] - China's infrastructure REITs market has seen a series of supportive policies since the pilot program was officially launched in April 2020[95][96] - Key policy milestones include the "Guidelines for Public Offering of Infrastructure Securities Investment Funds (Trial)" in August 2020 and the "14th Five-Year Plan" in March 2021, which emphasized the healthy development of infrastructure REITs[97] - The "Notice on Further Improving the Pilot Work of Infrastructure REITs" in July 2021 highlighted the importance of project quality and long-term healthy development of infrastructure REITs[97] - In January 2022, the Ministry of Finance and the State Taxation Administration introduced tax incentives for REITs, allowing deferred taxation on asset transactions or equity acquisitions during the establishment phase[97] - The "Opinions on Further Revitalizing Existing Assets and Expanding Effective Investment" in May 2022 identified key areas for revitalizing existing assets, including infrastructure projects with large scale, good current returns, or growth potential[97] - The "Outline of the Strategic Plan for Expanding Domestic Demand (2022-2035)" in December 2022 proposed the orderly development of infrastructure REITs to form a virtuous cycle between existing assets and new investments[98] - The total scale of infrastructure REITs in China reached 115.6 billion yuan, including 110.5 billion yuan from initial projects and 5.1 billion yuan from expansion projects[101] - The company has approximately 3.3 million square meters of pharmaceutical logistics storage assets and supporting facilities available for REITs issuance[102] - The Chinese government has introduced multiple policies to support the development of REITs, including expanding the scale of REITs issuance and encouraging private investment[99][100][101] - The company's REITs issuance is expected to provide significant equity-based funding, supporting rapid business development[102] - The Chinese government has issued policies to promote the high-quality development of the REITs market,

2024 年第一季度报告 单位：元 币种：人民币 证券代码：600998 证券简称：九州通 九州通医药集团股份有限公司 2024 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信 息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|-------------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | 40,472,147,237.18 ...

[Table_MainInfo] 公司研究/商业贸易/专营零售 证券研究报告 九州通（600998）公司研究报告 2024年04月08日 [Table_InvestInfo] 首次 民营医药流通龙头，数字化赋能增长 投资评级 优于大市 覆盖 股票数据 [Table_Summary] 0[4Ta月b0le3_日S收to盘ck价I（nf元o]） 8.18 投资要点： 52周股价波动（元） 6.52-17.14 总股本/流通A股（百万股） 3909/3909  综合流通平台，营收稳健增长。九州通成立于 1999 年，是科技驱动型的全 总市值/流通市值（百万元） 31975/31975 链医药产业综合服务商，主营业务包括数字化医药分销与供应链业务、总代 相关研究 品牌推广业务、医药工业自产及 OEM 业务、医药新零售与万店加盟业务、 [Table_ReportInfo] 医疗健康与技术增值服务、数字物流技术与供应链解决方案六大方面。 2019-2022 年，公司收入从 994.97 亿元增长至 1404.24 亿元，CAGR 达 12.17%；归母净利润从17.27亿元增长至20.85亿元，CAGR达6.49%；扣 ...

公司研究 | 动态跟踪 九州通 600998.SH 买入 （维持） 院外流通景气度提升，四大战略成果初显 股价（2024年03月27日） 7.75元 目标价格 9.23元 52周最高价/最低价 8.95/6.47元 总股本/流通A股（万股） 390,889/390,889 A股市值（百万元） 30,294 国家/地区 中国 核心观点 行业 医药生物 ⚫ 品牌总代业务有望打造利润端第二曲线。近两年，院外品牌总代业务景气度逐步提 报告发布日期 2024年03月28日 升，公司借助原有药品批发渠道，进一步加大对原有品牌总代业务的投入，并定位 为利润端的“第二曲线” 。根据23年3季报，品牌总代业务营业收入较上年同期 1周 1月 3月 12月 增长25.90%，毛利较上年同期增长41.49%。此前市场较为关注的毛利率指标也处 绝对表现% -3.73 -2.02 8.54 11.02 于逐步改善过程中，截止23H1公司品牌总代业务中药品部分毛利率已提升至 相对表现% -1.43 -2.25 3.55 23.72 25.95%，并大力引进优良品种 66 个，其中过亿品种 3 个，药品总代数达 915个， 沪深300% - ...

证券研究报告：医药生物 | 公司深度报告 2024年3月11日 股票投资评级 九州通(600998) 医药流通领域民营龙头，创新战略落地有望迎来估 买入|首次覆盖 值重塑 个股表现  民营医药流通企业龙头，向数字化、平台化、互联网化 转型升级 九州通 医药生物 九州通医药集团股份有限公司是一家科技驱动型的全链医药产 15% 10% 业综合服务商，是国内规模最大的民营医药流通企业。2022年我国医 5% 药流通行业CR4（国药集团、上海医药、华润医药以及九州通）市占 0% -5% 率由2019年的40%提升至48.7%，我国医药流通市场“国有3+民营1” -10% -15% 格局已然形成。九州通作为民营流通龙头企业，市占率由2019年5.1% -20% 提升至2022年6.28%。 -25% -30% 九州通在行业内率先实施由传统的医药分销业务向数字化、平台 2023-03 2023-05 2023-08 2023-10 2023-12 2024-03 化和互联网化的转型升级，并结合上下游客户的需求，推行“医药分 资料来源：聚源，中邮证券研究所 销+物流配送+产品推广”的综合服务模式，取得了显著的成效，公司 ...

证券代码：600998 证券简称：九州通 九州通医药集团股份有限公司 投资者关系活动记录表 （2023 年 12 月 14 日） □特定对象调研 R分析师会议 投资者关系 □媒体采访 £业绩说明会 活动类别 □新闻发布会 £路演活动 R现场参观 £其他 中信证券股份有限公司、兴业证券股份有限公司、中信建投 证券股份有限公司、国元证券股份有限公司、西部证券股份 参与单位名 有限公司、东吴证券股份有限公司、华泰证券股份有限公 ...

证券代码：600998 证券简称：九州通 公告编号：临 2023-137 九州通医药集团股份有限公司 关于举办“走进上市公司”主题投资者交流活动情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2023年12月12日，九州通医药集团股份有限公司（以下简称“九州通”或“公 司”）举办了“走进上市公司”主题投资者交流活动。本次活动通过参观公司发 展历程展厅、现代医药物流中心及开展座谈交流等方式，加强投资者对公司经营 成果、业务创新、战略规划及转型升级等情况的了解，深化与投资者的沟通交流， 增进公司市场认同和价值实现。活动相关情况公告如下： 一、 交流活动基本情况 （一） 时间：2023年12月12日 （二） 地点：九州通医药集团总部大厦、九州通现代医药物流中心 （三） 调研机构（排名不分先后）：中信证券股份有限公司、兴业证券股 份有限公司、中信建投证券股份有限公司、国元证券股份有限公司、西部证券股 份有限公司、东吴证券股份有限公司、华泰证券股份有限公司、安信证券股份有 限公司、甬兴证券股份有限公司、鑫元基金管理有限公司、 ...